RecruitingNCT06727669

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

Sponsor

Peking University People's Hospital

Enrollment

3,000 participants

Start Date

Nov 1, 2024

Study Type

OBSERVATIONAL

Conditions

Thrombophilia Thrombosis Arterial Thromboembolism Pulmonary Embolism Deep Vein Thrombosis Hemophilia A Hemophilia B Immune Thrombocytopenia Bleeding Disorder Thrombotic Microangiopathies Thrombotic Thrombocytopenic Purpura Hemophilia A, Acquired Disseminated Intravascular Coagulation Coagulation Factor Deficiency Hemophilia B, Acquired Platelet Dysfunction

Summary

This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.

Eligibility

Inclusion Criteria1

Patients who were diagnosed as thrombosis and hemostasis diseases.

Exclusion Criteria3

Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.
Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.
According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(5)

Peking University Insititute of Hematology, Peking University People's Hospital

Beijing, Beijing Municipality, China

Department of Hematology, Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Department of Hematology, Beijing Hospital

Beijing, Beijing Municipality, China

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Xinqiao Hospital, Army Military Medical University

Chongqing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06727669

Related Trials

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

NCT0700796220 locations

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT0710456540 locations

Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

NCT070809059 locations

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

NCT0556871916 locations

Platelet Volunteers, Longitudinal and Multi-omic Study

NCT071374291 location